A Phase I Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 against Crimean Congo Hemorrhagic Fever (CCHF-NP-1)
Phase 1
- Conditions
- Crimean Congo Hemorrhagic FeverMedDRA version: 20.1Level: PTClassification code: 10010685Term: Congo-Crimean haemorrhagic fever Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- CTIS2023-508556-18-00
- Lead Sponsor
- Karolinska Institutet
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method